Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck ( CheckMate 141)
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Two‐year follow‐up of a randomized phase
III
clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (
CheckMate
141)
Authors
Keywords
-
Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-25
DOI
10.1002/hed.26331
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
- (2019) Hiroki Ishihara et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma
- (2019) Takahiro Wakasaki et al. AURIS NASUS LARYNX
- Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
- (2019) Naoya Yamazaki et al. CANCER SCIENCE
- Increasing incidence of oral cancer in Hong Kong—Who, where…and why?
- (2019) Siu‐Wai Choi et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
- (2019) Robert L. Ferris et al. CLINICAL CANCER RESEARCH
- Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
- (2019) Hidehito Horinouchi et al. Cancer Medicine
- Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study
- (2019) Isaku Okamoto et al. ACTA OTO-LARYNGOLOGICA
- Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
- (2019) Nabil F. Saba et al. ORAL ONCOLOGY
- Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma
- (2019) Ryusuke Hori et al. Cancers
- Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
- (2019) Ken Masuda et al. BMC CANCER
- Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
- (2019) Khalil Saleh et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- (2018) E E Vokes et al. ANNALS OF ONCOLOGY
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
- (2018) Ranee Mehra et al. BRITISH JOURNAL OF CANCER
- Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
- (2018) Makoto Tahara et al. CANCER SCIENCE
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
- (2018) Song Ee Park et al. Journal of Thoracic Oncology
- CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
- (2018) Maura L. Gillison et al. ONCOLOGIST
- Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma
- (2018) Renata Ferrarotto et al. ORAL ONCOLOGY
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
- (2018) Paolo A. Ascierto et al. JAMA Oncology
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
- (2017) Kevin J Harrington et al. LANCET ONCOLOGY
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
- (2017) Gustavo Schvartsman et al. LUNG CANCER
- A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
- (2017) Naomi Kiyota et al. ORAL ONCOLOGY
- Trends in Head and Neck Cancer in South Korea Between 1999 and 2012
- (2016) Jeffrey D. Suh et al. Clinical and Experimental Otorhinolaryngology
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013
- (2015) Kota Katanoda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
- (2014) Vassiliki Saloura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009
- (2014) Tzer-Zen Hwang et al. INTERNATIONAL JOURNAL OF CANCER
- Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy
- (2012) Diocésio A.P. de Andrade et al. CURRENT OPINION IN ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now